Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Public Advisory - Jamp-Atorvastatin 40 mg tablets recalled due to risk of latex contamination | ||||||||||
By: PR Newswire Association LLC. - 06 Aug 2022 | Back to overview list |
|||||||||
OTTAWA, ON, Aug. 6, 2022 /CNW/ - Summary
Affected products
Issue Jamp Pharma Corporation is recalling one lot (MHC1403A) of Jamp-Atorvastatin 40 mg tablets due to possible contamination with latex pieces during manufacturing. A piece of latex was found in one tablet from the affected lot. Atorvastatin is a prescription drug used to treat high cholesterol and other fats (such as triglycerides) in the blood, and to prevent cardiovascular disease such as heart attacks. Ingesting latex can pose serious health risks for people with latex allergies, including severe allergic reactions (anaphylaxis). Symptoms of anaphylaxis include breathing difficulties, nausea, vomiting, and low blood pressure. Anaphylaxis can be life threatening. In addition, foreign material in the tablets may change their shape, which could make them difficult to swallow and lead to choking. The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified. What you should do
Alert / recall type: Public Advisory Également disponible en français SOURCE Health Canada ![]() |
||||||||||
|
||||||||||
![]() | Back to overview list |